Can Improved Use of Biomarkers Alter the Fate of PI3K Pathway Inhibitors in the Clinic?
Can Improved Use of Biomarkers Alter the Fate of PI3K Pathway Inhibitors in the Clinic?
复制标题
更好地利用生物标志物能否改变PI3K通路抑制剂在临床上的命运？
DOI：
10.1158/0008-5472.can-21-2035
复制
发表时间：
2021-12-15
期刊：
影响因子：
11.2
通讯作者：
Toker A
中科院分区：
文献类型：
--
作者：
Erickson EC;Toker A
癌症中PI3K通路改变的高频率促使人们付出诸多努力来研发针对该网络的药物。尽管已经研发出许多强效且具有选择性的抑制剂，并在临床前模型中进行了评估，但这些抑制剂获得临床批准的进展有限。在此，我们探讨迫切需要开发更完善的生物标志物策略，以指导患者选择，并改进对患者对PI3K通路抑制剂反应的评估，从而解决围绕这些化合物在癌症患者中的疗效和耐受性等尚未解决的问题 。
The high frequency of PI3K pathway alterations in cancer has motivated numerous efforts to develop drugs targeting this network. Although many potent and selective inhibitors have been developed and evaluated in preclinical models, their progress to clinical approval has been limited. Here we discuss the pressing need to develop improved biomarker strategies to guide patient selection and improve assessment of patient responses to PI3K pathway inhibitors to address unresolved issues surrounding the efficacy and tolerability of these compounds in cancer patients.